Intelligence Feed event · Equity · 2026-10-07

    Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes

    Question

    Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes

    Direct answer

    Clinical-stage vaccine developer Vaxcyte announced the pricing of a $1.0 billion concurrent capital raise to finance clinical programs. The transaction includes 7.4 million common shares at $64.00 each and $500 million of 1.50% convertible senior notes maturing in 2032. The offering secures long-term liquidity for pipeline execution while introducing standard convertible arbitrage selling and equity dilution dynamics during the settlement period.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-07
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes”, revision 1, evidence through 2026-10-07. https://marketontology.com/market-events/2026-10-07/vaxcyte-prices-1-0b-concurrent-offering-of-common-stock-and-convertible-notes-82738a

    EQUITY
    Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes
    Clinical-stage vaccine developer Vaxcyte announced the pricing of a $1.0 billion concurrent capital raise to finance clinical programs. The transaction includes 7.4 million common shares at $64.00 each and $500 million of 1.50% convertible senior notes maturing in 2032. The offering secures long-term liquidity for pipeline execution while introducing standard convertible arbitrage selling and equity dilution dynamics during the settlement period.
    PCVX
    Impact
    67
    OCT 7
    SIG
    90%
    PCVX
    Vaxcyte Prices $1.0B Concurrent Offering of Common Stock and Convertible Notes
    Clinical-stage vaccine developer Vaxcyte announced the pricing of a $1.0 billion concurrent capital raise to finance clinical programs. The transaction includes 7.4 million common shares at $64.00 each and $500 million of 1.50% convertible senior notes maturing in 2032. The offering secures long-term liquidity for pipeline execution while introducing standard convertible arbitrage selling and equity dilution dynamics during the settlement period.
    → Issuing 7.4 million new shares at $64.00 and $500 million convertible notes expands PCVX share float and introduces convertible arbitrage delta-hedging pressure on the equity.
    Impact
    Clinical-stage vaccine developer Vaxcyte announced the pricing of a $1.0 billion concurrent capital raise to finance clinical programs. The transaction includes 7.4 million common shares at $64.00 each and $500 million of 1.50% convertible senior notes maturing in 2032. The offering secures long-term liquidity for pipeline execution while introducing standard convertible arbitrage selling and equity dilution dynamics during the settlement period.
    Affected
    PCVX
    Transmission
    Issuing 7.4 million new shares at $64.00 and $500 million convertible notes expands PCVX share float and introduces convertible arbitrage delta-hedging pressure on the equity.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    PCVXequity dilution and convertible arbitrage short-selling pressureMixed1-5dPriced $1B offering including 7.4M shares at $64.00 and $500M convertible debt.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    PCVXMixed66.96 2026-10-07-2.90%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month